Biological
Ad26.Mos4.HIV clinical trials
How studies write it
Studies that test it under each name
Name
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
Janssen Vaccines & Prevention B.V. (5) · Boris Juelg, MD PhD (1) · Henry M. Jackson Foundation for the Advancement of Military Medicine (1)
Often tested with
Tested in the same studies.
VRC07-523LS (2) · PGT-121 (1) · PGDM1400 (1) · GP 140 (1) · PGDM1400LS (1) · Nogapendekin alfa inbakicept (1) · Monophosphoryl lipid A (1) · Saponin QA-21V1 (1)
Studies
Open first, then newest update. How each study uses Ad26.Mos4.HIV is read from its arms, and is right about nine times in ten.
Testing it · 7
- Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsCompletedPhase 1/2Boris Juelg, MD PhDNCT04983030Written as Ad26.Mos4.HIV
- A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected AdultsCompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT02935686Written as Ad26.Mos4.HIV
- Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected AdultsCompletedPhase 1/2Janssen Vaccines & Prevention B.V.NCT02788045Written as Ad26.Mos4.HIV
- A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral TreatmentCompletedPhase 1Janssen Vaccines & Prevention B.V.NCT03307915Written as Ad26.Mos4.HIV
- A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender IndividualsCompletedPhase 3Janssen Vaccines & Prevention B.V.NCT03964415Written as Ad26.Mos4.HIV
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnPhase 1Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05769569Written as Ad26.Mos4.HIV
- A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan AfricaTerminatedPhase 2Janssen Vaccines & Prevention B.V.NCT03060629Written as Ad26.Mos4.HIV